However, the incidence of other gene alterations, e.g. BRAF and PIK3CA mutations, involved in the response to anti-EGFR therapies in colorectal cancer [8] has not been studied in anal carcinoma. This evidence concerns the gene PIK3CA and anal carcinoma.